IMPORTANT: Read the Prep & Injection Guide for proper reconstitution, syringe sizing, and injection protocols. Mistakes here can compromise your research.
This triple blend combines BPC-157 (5 mg), TB-500 (5 mg), and Cartalax (10 mg) in a single vial. BPC-157 is a stable gastric pentadecapeptide studied for angiogenesis, tendon-to-bone healing, gut repair, and anti-inflammatory activity. TB-500 (Thymosin Beta-4 fragment) is researched for cell migration, actin regulation, tissue flexibility, and reduced scar formation. Cartalax (Ala-Glu-Asp) is a short bioregulator peptide from the Khavinson research program studied for cartilage and connective-tissue support. Together the trio is researched for comprehensive healing of muscle, tendon, ligament, joint, and cartilage tissue.
— BPC-157 5 mg + TB-500 5 mg + Cartalax 10 mg Blend Vial —
Reconstitute: Add 2.0 mL (200 units) bacteriostatic water.
Administration: Subcutaneous injection.
Timing: May be taken at any time of day or night; dosing does not require fasting.
Storage: Lyophilized: freeze at −20 °C; reconstituted: refrigerate at 2–8 °C, avoid freeze-thaw cycles.
Schedule: Once-daily injections.
Cycle Length: 8-week cycle, followed by a 4-week washout period. A defined cycle and washout are REQUIRED because of the inclusion of TB-500 and Cartalax.
Goal: Support soft-tissue, tendon, ligament, joint, and cartilage healing based on preclinical evidence.
Standard Protocol
| Phase | Dose | Syringe (U-100) |
|---|---|---|
| Weeks 1–2 | ~150 mcg BPC-157 + ~150 mcg TB-500 + ~300 mcg Cartalax | 6 units (0.06 mL), 1x/day |
| Weeks 3–8 | ~200 mcg BPC-157 + ~200 mcg TB-500 + ~400 mcg Cartalax | 8 units (0.08 mL), 1x/day |
Maximum Protocol
| Phase | Dose | Syringe (U-100) |
|---|---|---|
| Weeks 1–2 | ~250 mcg BPC-157 + ~250 mcg TB-500 + ~500 mcg Cartalax | 10 units (0.10 mL), 1x/day |
| Weeks 3–8 | ~150 mcg BPC-157 + ~150 mcg TB-500 + ~300 mcg Cartalax | 6 units (0.06 mL), 1x/day |
Note: The Maximum protocol intentionally steps DOWN after week 2 — a higher loading phase followed by a lower maintenance dose. This is correct per the source protocol, not a typo.
- Synergistic healing of muscle, tendon, ligament, and connective-tissue injuries.
- Cartilage and joint support from the Cartalax bioregulator component.
- Accelerates wound healing through angiogenesis (BPC-157).
- Promotes cell migration to injury sites via actin regulation (TB-500).
- May reduce scar tissue formation and improve tissue flexibility.
- Reduces systemic and localized inflammation.
- Supports gut-lining repair and gastrointestinal health (BPC-157).
- Studied for joint comfort and improved mobility.
- May improve recovery time from training and injury.
- Tendon & ligament injuries (e.g. Achilles, rotator cuff)
- Cartilage degradation, joint injuries, and chronic joint pain
- Arthritis / Osteoarthritis
- Muscle strains and tears
- Post-surgery recovery
- Chronic inflammatory conditions
- Ulcers and inflammatory bowel conditions (BPC-157 component)
- Slow-healing wounds
While side effects are not common, you may experience:
- Nausea
- Headaches
- Dizziness
- Fatigue or lethargy
- Gas/bloating or appetite changes
- Irritation or redness at the injection site
- Do not use when pregnant or nursing.
- Do not use with active cancer — BPC-157 and TB-500 promote angiogenesis and cell migration.
- Do not take if you have chronic kidney disease; use caution with liver disease.
- Exercise caution with protein allergies.
- If you have an autoimmune disorder, it may be worsened since BPC-157 stimulates the immune system.
- Exercise caution with heart conditions, as BPC-157 may cause a rise in blood pressure.
- Observe the mandatory 4-week washout after each 8-week cycle (required due to TB-500 and Cartalax).
This blend is itself a stack of BPC-157, TB-500, and Cartalax. Common research pairings to extend it include:
- Ipamorelin – For stimulating GH release and promoting full-body repair
- CJC No DAC – Enhances GH pulsatility alongside Ipamorelin
- GHK-Cu – Known for wound healing and skin repair
- Sermorelin – A GHRH analog to further support repair and recovery
PubMed-linked citations for verification. Many studies are animal/in-vitro.
- Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon. J Orthop Res. 2003;21(6):976-82. PMID: 12740856
- Therapy with gastric pentadecapeptide BPC 157 for various muscle and tendon pathologies. Eur J Pharmacol. 2005;510(1-2):113-7. PMID: 16024785
- Thymosin beta 4 accelerates wound healing. J Invest Dermatol. 1999;113(3):364-8. PMID: 10469335
- Thymosin beta4 promotes cardiac repair and cardiomyocyte survival. Nature. 2004;432(7016):466-72. PMID: 15565145
- Pentadecapeptide BPC 157 — a therapy for various conditions. J Pharmacol Sci. 2018;138(1):1-8. PMID: 29522634
- Cartalax (Ala-Glu-Asp) — short peptide bioregulator studied for fibroblast function and connective-tissue gene expression in the Khavinson peptide research program. St. Petersburg Institute of Bioregulation and Gerontology peptide bioregulator studies.
Research Use Only. All information on this page is for educational purposes only and is not medical advice. PepSherpa does not sell peptides. Consult a licensed healthcare provider before making any health decisions. Many of the studies cited are preclinical (animal/in-vitro).
